Novo Nordisk A/S: Mim8 phase 1 & 2 data demonstrates potential as once monthly treatment for people with haemophilia A
July 11, 2022 09:45 ET
|
Novo Nordisk A/S
No thromboembolic events or related serious adverse events reported over 12-week observation period in FRONTIER1 study.1 London, UK, 11 July 2022 – Novo Nordisk announced that the phase 1 & 2...
Novo Nordisk A/S: Phase 3 data for concizumab show 86% reduction in treated bleeds in haemophilia A or B with inhibitors
July 10, 2022 10:02 ET
|
Novo Nordisk A/S
Data presented today show a reduction in treated spontaneous and traumatic bleeds and mean annualised bleeding rate (ABR) of 1.7 with concizumab1 London, UK, 10 July 2022 – Novo Nordisk announced the...
Novo Nordisk A/S: Sogroya® data show potential as once-weekly treatment in children living with growth hormone deficiency
June 12, 2022 12:31 ET
|
Novo Nordisk A/S
Investigational phase 3 data for Sogroya® (somapacitan) injection in children with growth hormone deficiency presented today at the ENDO 2022 Congress1 Atlanta, Georgia (US), 12 June 2022 – Today,...
PureWay® Compliance Partners With Medical Device and Pharmaceutical Manufacturers to Bring Safe and Environmentally Friendly Disposal to Patients At-Home
May 26, 2022 11:00 ET
|
PureWay® Compliance, Inc.
HOUSTON, May 26, 2022 (GLOBE NEWSWIRE) -- Each year, approximately 9 million patients receive at least 3 billion injections outside of healthcare facilities. These medications are used to manage a...
Novo Nordisk A/S – Share repurchase programme
March 07, 2022 08:08 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 7 March 2022 – On 2 February 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council...
Notice for the Annual General Meeting of Novo Nordisk A/S
February 21, 2022 09:05 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 21 February 2022 – The Annual General Meeting of Novo Nordisk A/S will be held on: Thursday 24 March 2022 at 14.00 (CET) The Annual General Meeting is held as a partially...
Novo Nordisk A/S: Share repurchase programme
February 21, 2022 06:09 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 21 February 2022 – On 2 February 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...
Research Ethics Board approves amendment to Canadian Treatments for COVID-19 (CATCO) Trial to include LSALT Peptide (Metablok)
January 04, 2022 07:25 ET
|
Arch Biopartners
TORONTO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch Biopartners”, “Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug...
Trading in Novo Nordisk shares by board members, executives and associated persons on 5 November 2021
November 05, 2021 17:02 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 5 November 2021 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in...
Novo Nordisk A/S – Share repurchase programme
November 05, 2021 16:55 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 5 November 2021 — As part of the up to DKK 20.0 billion 2021 share repurchase programme, Novo Nordisk A/S has now initiated a new share repurchase programme for an amount of up to...